Humacyte is trading 10.51% down at $0.40, with no clear company-specific announcement identified for the October 9 move. - The decline extends a 5.34% drop on October 8. Biotech was reported up 2.50%, so available evidence does not point to sector strength as the reason for the decline. - The latest located company release was the September 9 Symvess shelf-life update. Barclays initiated Equal-Weight coverage with a $0.50 target on October 7, but no source linked it directly to the October 9 move.